Form 4: Phathom Pharmaceuticals Officer Reports Equity Transactions

Phathom Pharmaceuticals' Principal Accounting Officer, Robert Charles Breedlove, reported the acquisition of restricted stock units and performance-based shares, alongside tax-related share dispositions.

Summary

• Robert Charles Breedlove, Principal Accounting Officer of Phathom Pharmaceuticals, Inc., reported several equity transactions on February 27, 2026.
• Acquired 13,000 shares of Common Stock through a grant of Restricted Stock Units (RSUs). These RSUs vest in three equal annual installments starting February 27, 2026.
• Acquired 2,790 shares of Common Stock upon the vesting of performance stock units granted on February 27, 2025, following the satisfaction of performance criteria.
• Disposed of 964 shares of Common Stock at a price of $12.56 per share to satisfy tax withholding obligations related to the vesting of performance stock units.
• Disposed of 414 shares of Common Stock at a price of $12.56 per share to satisfy tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Mr. Breedlove directly beneficially owns 61,480 shares of Common Stock and indirectly owns 6,945.4 shares through a 401(k) plan, totaling 68,425.4 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting routine executive compensation and the achievement of performance milestones, which are generally favorable for executive retention and motivation, despite the tax-related share dispositions.

Positives

• Grant of 13,000 Restricted Stock Units (RSUs) to the Principal Accounting Officer, indicating continued incentive and alignment with company performance.
• Vesting of 2,790 performance stock units, signifying the achievement of previously set performance criteria.

Negatives

• Disposition of 1,378 shares (964 + 414) of Common Stock to cover tax withholding obligations, which reduces the officer's direct beneficial ownership.

Future Outlook

The newly granted 13,000 Restricted Stock Units (RSUs) will vest in three equal annual installments on the first three anniversaries of February 27, 2026, subject to the reporting person's continued service.

Industry Context

StockSavvy.ai notes that equity compensation, including RSUs and performance stock units, is a standard practice across the biotechnology and pharmaceutical industries to incentivize and retain key executives. These grants align management's interests with shareholder value creation, particularly in companies like Phathom Pharmaceuticals focused on drug development and commercialization.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) for executive compensation is a common practice among publicly traded pharmaceutical companies, aligning with compensation structures seen at peers such as Acadia Pharmaceuticals Inc. (ACAD) or Neurocrine Biosciences, Inc. (NBIX).
• The vesting schedule of one-third annually over three years for RSUs is a typical industry standard for long-term incentive plans, designed to promote executive retention and sustained performance.

Stakeholder Impact

• Shareholders: The grant of RSUs and vesting of performance units align the Principal Accounting Officer's interests with shareholder value, potentially encouraging long-term performance.
• Employees: Reflects standard compensation practices for key personnel, which can positively influence morale and retention.

Next Steps

• The remaining two-thirds of the 13,000 RSUs granted on February 27, 2026, are expected to vest on the second and third anniversaries of that date, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation and tax-related share dispositions, which are not typically significant drivers of stock price movement. It provides transparency into insider holdings but does not present new fundamental information to warrant a change in investment recommendation based solely on this filing.

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, Insider Trading, Restricted Stock Units, Performance Stock Units, Equity Compensation, Officer Transactions, Stock Ownership